Roivant Sciences (NASDAQ:ROIV) Sets New 1-Year Low – Should You Sell?

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) reached a new 52-week low during trading on Monday . The stock traded as low as $9.92 and last traded at $10.15, with a volume of 451980 shares changing hands. The stock had previously closed at $10.38.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on ROIV shares. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Roivant Sciences currently has an average rating of “Buy” and a consensus target price of $17.10.

Roivant Sciences Stock Performance

The business has a 50 day simple moving average of $10.74 and a 200-day simple moving average of $11.40. The stock has a market capitalization of $7.15 billion, a P/E ratio of -66.96 and a beta of 1.26.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Equities research analysts forecast that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Insider Activity

In related news, COO Eric Venker sold 434,478 shares of the business’s stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $10.82, for a total value of $4,701,051.96. Following the completion of the transaction, the chief operating officer now owns 1,127,290 shares in the company, valued at $12,197,277.80. The trade was a 27.82 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Rakhi Kumar sold 227,500 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the transaction, the chief accounting officer now owns 163,264 shares in the company, valued at approximately $1,702,843.52. The trade was a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,395,541 shares of company stock valued at $15,028,538. Insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Roivant Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. lifted its holdings in shares of Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock valued at $28,000 after purchasing an additional 1,948 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new position in Roivant Sciences during the fourth quarter worth approximately $39,000. GAMMA Investing LLC raised its stake in Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after acquiring an additional 1,288 shares during the period. PNC Financial Services Group Inc. boosted its position in Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock worth $84,000 after purchasing an additional 1,507 shares during the period. Finally, Quarry LP increased its holdings in shares of Roivant Sciences by 50.0% in the third quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after purchasing an additional 2,500 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.